Get the Stockscreener App
160.07
11.83%
-22.53
After Hours:
160.00
-0.075
-0.05%
Spruce Biosciences Inc stock is traded at $160.07, with a volume of 746.43K.
It is down -11.83% in the last 24 hours and down -70.37% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
See More
Previous Close:
$182.60
Open:
$140
24h Volume:
746.43K
Relative Volume:
1.80
Market Cap:
$90.13M
Revenue:
$7.10M
Net Income/Loss:
$-39.43M
P/E Ratio:
-170.29
EPS:
-0.94
Net Cash Flow:
$-46.50M
1W Performance:
+1,709%
1M Performance:
-70.37%
6M Performance:
-86.69%
1Y Performance:
-90.34%
1-Day Range:
$138.01
$175.00
1-Week Range:
$7.88
$240.00
52-Week Range:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
160.07 | 102.81M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
Spruce Biosciences (SPRB) Secures $50M for Therapy Advancements - GuruFocus
Medical Stocks To ConsiderOctober 6th - MarketBeat
Spruce Biosciences (SPRB) Secures $50M for Enzyme Replacement Therapy - GuruFocus
Spruce Biosciences (SPRB) Secures $50 Million for Enzyme Therapy Development - GuruFocus
Spruce Biosciences secures $50 million in private placement - Investing.com
Spruce Biosciences (SPRB) Secures $50M in Private Placement for Therapy Advancement - GuruFocus
Spruce Biosciences announces $50.0 million private placement financing - MarketScreener
Spruce Biosciences Announces $50.0 Million Private Placement Financing - Business Wire
Small Cap Stocks To Follow Today – October 6th - Defense World
Three Biotech Stocks Jump After Big Regulatory Wins - Finimize
Spruce Biosciences Stock: Emergent Surges and Market Implications - timothysykes.com
Spruce Biosciences’ Breakthrough: Stock Skyrockets - StocksToTrade
Spruce Biosciences Soars: What’s Driving the Surge? - timothysykes.com
Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade) - Seeking Alpha
SPRB Stock Hits 19-Month High Amid Trading Halts - Stocktwits
Spruce Biosciences Stock Surges: Analyzing Breakthrough - StocksToTrade
Spruce Biosciences (SPRB) Stock: Rare Disease Breakthrough Sends Shares Soaring Over 1,300% - parameter.io
This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. - Barron's
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025) - ts2.tech
Spruce Biosciences (SPRB) Stock Soars 1,378% on FDA Breakthrough Status - MoneyCheck
Biotech And Tech Stocks Rally On Breakthrough News And Partnerships - Finimize
Morning Market Movers: GLTO, CISS, SPRB, LXEO See Big Swings - RTTNews
Spruce Biosciences Almost Doubles Premarket as FDA Grants Breakthrough Therapy Designation for Tralesinidase Alfa in Sanfilippo Syndrome - MarketScreener
Spruce Biosciences Stock Nearly Doubles Premarket: 'Pharma Bro' Martin Shkreli Sees 280% Upside - Stocktwits
Why Is Spruce Biosciences Stock (SPRB) Surging Today? - TipRanks
Spruce Biosciences (SPRB) Stock Jumps 30% After Hours Following Red Hot Rally On Monday: Here's Why - Benzinga
Small Cap Stocks To Follow TodayOctober 6th - MarketBeat
Spruce Biosciences Stock Resumes Trading: What to Expect? - timothysykes.com
Why This Biotech Stock Just Rocketed Almost 1,400% - Investor's Business Daily
Spruce Biosciences Surges on FDA Breakthrough: Is SPRB’s Rally Sustainable? - Azat TV
Why Spruce Biosciences Just Skyrocketed More Than 1,600% - inkl
SPRB’s Stock Market Moves: Key Insights - StocksToTrade
Spruce Biosciences (SPRB) Surges 1,244% on FDA Breakthrough Ther - GuruFocus
FDA Grants Breakthrough Therapy Status to Spruce Biosciences’ TA-ERT for MPS IIIB - el-balad.com
Spruce Bio jumps after breakthrough therapy status for enzyme replacement therapy - Seeking Alpha
Promising Pharmaceutical Stocks Worth WatchingOctober 6th - MarketBeat
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade? - ts2.tech
SPRB’s Wild Ride: Understanding Today’s Market Move - timothysykes.com
Spruce Biosciences’ Blockchain Breakthrough - StocksToTrade
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge - Benzinga
Spruce Biosciences shares pop after FDA grants Breakthrough Therapy Designation for rare disease treatment - Proactive financial news
Spruce Biosciences soars after FDA's 'breakthrough therapy' tag for co's drug - TradingView
Spruce Biosciences Stock Is Soaring Today: Here's Why - Benzinga
Why Did Spruce Biosciences Stock Quadruple Today? - Stocktwits
Spruce Biosciences Rockets Sky-High on FDA Breakthrough for Rare Kids’ Brain Therapy - RagingBull
Spruce Biosciences (SPRB) Gains FDA Breakthrough Designation for Key Therapy - GuruFocus
Spruce Biosciences' TA-ERT Secures FDA's Breakthrough Therapy Designation, Stock Surges - Nasdaq
FDA grants breakthrough therapy designation to Spruce’s MPS IIIB drug By Investing.com - Investing.com Canada
Spruce Biosciences receives U.S. FDA breakthrough therapy designation for Tralesinidase Alfa enzyme replacement therapy in Sanfilippo syndrome type B (MPS IIIB) - MarketScreener
Spruce Biosciences stock soars after receiving FDA Breakthrough Therapy status - Investing.com
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
4.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):